

CLEO Continues on Pathway for U.S. Regulatory Approval with Positive FDA Feedback

Highlights

- **CLEO receives positive feedback from the U.S. FDA at a second pre-submission meeting for its Ovarian Cancer Pre-Surgical Triage Test**
- **FDA guidance supports CLEO's clinical trial design and regulatory positioning**
- **Feedback reinforces alignment with FDA expectations, reduces regulatory risk and positions CLEO strongly ahead of its upcoming 510(k) submission.**

MELBOURNE, AUSTRALIA, 15th September 2025: Ovarian Cancer diagnostics company, **Cleo Diagnostics Limited (ASX:COV) (CLEO or the Company)** is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (**FDA**) at its second pre-submission meeting for the Company's first commercial product, being its Ovarian Cancer Pre-Surgical Triage Test.

CLEO's Ovarian Cancer Test Progresses Towards U.S. Commercial Launch

Following its initial meeting with the FDA last year, CLEO has completed its second pre-submission meeting with the Company's Quality and Regulatory Manager, Emma Lester, attending in person at the FDA Headquarters in Silver Spring, Maryland. The focus of the meeting was on technical details surrounding the following:

- = Clinical trial design;
- = Sample stability;
- = Use of biobank samples to support critical studies;
- = Clinical specificity (the ability of its test to correctly identify ovarian cancer without mistake identifying other conditions); and
- = Intended use and clinical workflow.

The meeting was highly constructive, with the FDA offering positive and detailed feedback. The guidance reinforces confidence that CLEO's clinical trial and broader strategic direction remain aligned with regulatory expectations.

Importantly, this feedback enables CLEO to further enhance the robustness its pivotal clinical trial design by strengthening data collection processes to support a high-quality submission. In addition, it helps reduce regulatory risk ahead of the Company's 510(k) submission - an expedited approval process for technologies that demonstrate substantial equivalence to an existing predicate device. CLEO will remain actively engaged with U.S. regulatory bodies leading up to its submission next year.

Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

Directors
Chair and Non-Executive Director **Adrien Wing**
Chief Executive Officer and Executive Director **Dr Richard Allman**
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**
Non-Executive Director **Lucinda Nolan**

Commenting on the meeting, CLEO Chief Executive Officer, Dr Richard Allman, said:

"This second round of positive feedback from the FDA marks another important milestone in our regulatory journey. The FDA's guidance enables us to strengthen our trial design and move forward with greater confidence in our 510(k) strategy. It supports our approach and underscores the opportunity CLEO has to deliver a clinically meaningful and accessible solution to support more appropriate surgical triage for ovarian cancer."

-ENDS-

This ASX announcement was authorised for release on behalf of the CLEO Diagnostics Ltd Board.

For more information, contact:

Richard Allman
Chief Executive Officer
+613 9614 0000
office@cleodx.com

Dayna Louca
Head of Corporate Development
+61 409 581 972
dayna.louca@cleodx.com

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

About Cleo Diagnostics Ltd ASX:COV

CLEO aims to bring to market a simple blood test for the accurate and early diagnosis of Ovarian Cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by Ovarian Cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, CLEO has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for Ovarian Cancer significantly as seen with other cancers. CLEO is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all Ovarian Cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

